BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 35733414)

  • 1. Pharmacokinetics of extrafine beclometasone dipropionate/formoterol fumarate/glycopyrronium bromide in adolescent and adult patients with asthma.
    Kuna P; Jerzynska J; Martini M; Vele A; Barneschi I; Mariotti F; Georges G; Ciurlia G
    Pharmacol Res Perspect; 2022 Aug; 10(4):e980. PubMed ID: 35733414
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics and pharmacodynamics of an extrafine fixed pMDI combination of beclometasone dipropionate/formoterol fumarate in adolescent asthma.
    Kuna P; Govoni M; Lucci G; Scuri M; Acerbi D; Stelmach I
    Br J Clin Pharmacol; 2015 Sep; 80(3):569-80. PubMed ID: 25808292
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ethnic Sensitivity Study of the Extrafine, Single-Inhaler, Triple Therapy Beclomethasone Dipropionate, Formoterol Fumarate, and Glycopyrronium Bromide Pressurized Metered Dose Inhaler in Japanese and Caucasian Healthy Individuals: A Randomized, Double-Blind, Single-Dose Crossover Study.
    Cella M; Täubel J; Delestre-Levai I; Tulard A; Vele A; Georges G
    Clin Ther; 2021 Nov; 43(11):1934-1947.e4. PubMed ID: 34600734
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics, pharmacodynamics and safety of a novel extrafine BDP/FF/GB combination delivered via metered-dose inhaler in healthy Chinese subjects.
    Hu C; Miao J; Shu S; Wang Y; Zhu X; Luo Z
    Eur J Pharm Sci; 2020 Mar; 144():105198. PubMed ID: 31862312
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Two-Period Open-Label, Single-Dose Crossover Study in Healthy Volunteers to Evaluate the Drug-Drug Interaction Between Cimetidine and Inhaled Extrafine CHF 5993.
    Mariotti F; Ciurlia G; Spaccapelo L; Muraro A; Acerbi D
    Eur J Drug Metab Pharmacokinet; 2017 Apr; 42(2):269-279. PubMed ID: 27209586
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluating the pharmacokinetics of beclometasone dipropionate/formoterol fumarate/glycopyrronium bromide delivered via pressurised metered-dose inhaler using a low global warming potential propellant.
    Rony F; Cortellini M; Guasconi A; Mathews KS; Piccinno A; Poli G; Vanhoutte F; Klein J
    Pulm Pharmacol Ther; 2024 Apr; 85():102299. PubMed ID: 38663512
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The bronchodilator effects of extrafine glycopyrronium added to combination treatment with beclometasone dipropionate plus formoterol in COPD: A randomised crossover study (the TRIDENT study).
    Singh D; Schröder-Babo W; Cohuet G; Muraro A; Bonnet-Gonod F; Petruzzelli S; Hoffmann M; Siergiejko Z;
    Respir Med; 2016 May; 114():84-90. PubMed ID: 27109816
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of Dry-Powder Inhaler and Pressurized Metered-Dose Inhaler Formulations of Extrafine Beclomethasone Dipropionate/Formoterol Fumarate/Glycopyrronium in Patients with COPD: The TRI-D Randomized Controlled Trial.
    Beeh KM; Kuna P; Corradi M; Viaud I; Guasconi A; Georges G
    Int J Chron Obstruct Pulmon Dis; 2021; 16():79-89. PubMed ID: 33488071
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lung Deposition of Inhaled Extrafine Beclomethasone Dipropionate/Formoterol Fumarate/Glycopyrronium Bromide in Healthy Volunteers and Asthma: The STORM Study.
    Usmani OS; Baldi S; Warren S; Panni I; Girardello L; Rony F; Taylor G; DeBacker W; Georges G
    J Aerosol Med Pulm Drug Deliv; 2022 Aug; 35(4):179-185. PubMed ID: 35128939
    [No Abstract]   [Full Text] [Related]  

  • 10. Pharmacokinetic profile of beclometasone dipropionate/formoterol fumarate administered through a novel dry-powder inhaler in Chinese healthy volunteers.
    Luo Z; Lucci G; Santoro L; Topole E; Mariotti F
    Pulm Pharmacol Ther; 2022 Jun; 73-74():102129. PubMed ID: 35525480
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The systemic exposure to inhaled beclometasone/formoterol pMDI with valved holding chamber is independent of age and body size.
    Govoni M; Piccinno A; Lucci G; Poli G; Acerbi D; Baronio R; Singh D; Kuna P; Chawes BL; Bisgaard H
    Pulm Pharmacol Ther; 2015 Feb; 30():102-9. PubMed ID: 24746942
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Systemic exposure to inhaled beclometasone/formoterol DPI is age and body size dependent.
    Chawes BL; Govoni M; Kreiner-Møller E; Vissing NH; Poorisrisak P; Mortensen L; Nilsson E; Bisgaard A; Dossing A; Deleuran M; Skytt NL; Samandari N; Piccinno A; Sergio F; Ciurlia G; Poli G; Acerbi D; Singh D; Bisgaard H
    Respir Med; 2014 Aug; 108(8):1108-16. PubMed ID: 24993817
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Acute cardiovascular safety of two formulations of beclometasone dipropionate/formoterol fumarate in COPD patients: A single-dose, randomised, placebo-controlled crossover study.
    Singh D; Ciurlia G; Piccinno A; Muraro A; Bocchi M; Scuri M
    Pulm Pharmacol Ther; 2017 Feb; 42():43-51. PubMed ID: 28065679
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Extrafine beclomethasone/formoterol combination via a dry powder inhaler (NEXThaler(®)) or pMDI and beclomethasone monotherapy for maintenance of asthma control in adult patients: A randomised, double-blind trial.
    Kanniess F; Scuri M; Vezzoli S; Francisco C; Petruzzelli S
    Pulm Pharmacol Ther; 2015 Feb; 30():121-7. PubMed ID: 25088067
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of extrafine beclomethasone dipropionate/formoterol fumarate dry powder inhaler and pressurized metered-dose inhaler in Chinese patients with asthma: the FORTUNE study.
    Zheng J; Zhang J; Fu X; Lin C; Zhang X; Mei X; Corradi M; Cappellini G; Calabro E; Zhu C; Topole E
    J Asthma; 2024 Apr; 61(4):360-367. PubMed ID: 37878325
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bronchodilating effects of a new beclometasone dipropionate plus formoterol fumarate formulation via pressurized metered-dose inhaler in asthmatic children: a double-blind, randomized, cross-over clinical study.
    Pohunek P; Varoli G; Reznichenko Y; Mokia-Serbina S; Brzostek J; Kostromina V; Kaladze M; Muraro A; Carzana E; Armani S; Kaczmarek J
    Eur J Pediatr; 2021 May; 180(5):1467-1475. PubMed ID: 33404895
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Systemic exposure and implications for lung deposition with an extra-fine hydrofluoroalkane beclometasone dipropionate/formoterol fixed combination.
    Bousquet J; Poli G; Acerbi D; Monno R; Ramael S; Nollevaux F
    Clin Pharmacokinet; 2009; 48(6):347-58. PubMed ID: 19650674
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetic comparison of inhaled fixed combination vs. the free combination of beclomethasone and formoterol pMDIs in asthmatic children.
    Chawes BL; Piccinno A; Kreiner-Møller E; Vissing NH; Poorisrisak P; Mortensen L; Nilson E; Bisgaard A; Dossing A; Deleuran M; Skytt NL; Samandari N; Sergio F; Ciurlia G; Poli G; Acerbi D; Bisgaard H
    Br J Clin Pharmacol; 2013 Apr; 75(4):1081-8. PubMed ID: 22978252
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of single-inhaler extrafine triple therapy versus inhaled corticosteroid plus long-acting beta2 agonist in eastern Asian patients with COPD: the TRIVERSYTI randomised controlled trial.
    Zheng J; Baldi S; Zhao L; Li H; Lee KH; Singh D; Papi A; Grapin F; Guasconi A; Georges G
    Respir Res; 2021 Mar; 22(1):90. PubMed ID: 33757520
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness of single-inhaler extrafine beclometasone dipropionate/formoterol fumarate/glycopyrronium in patients with uncontrolled asthma in England.
    Orlovic M; Magni T; Lukyanov V; Guerra I; Madoni A
    Respir Med; 2022 Sep; 201():106934. PubMed ID: 35872377
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.